ARTICLE | Company News
Crucell, J&J deal
August 20, 2001 7:00 AM UTC
JNJ's Centocor Inc. subsidiary (Malvern, Penn.) will develop and commercialize CRUX's CD46-specific human antibodies to treat cancer. Centocor is responsible for global development and manufacturing,...